These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9755905)

  • 21. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
    Levron JC; Ropert R
    Encephale; 1987; 13(2):83-7. PubMed ID: 2885172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of fluphenazine in plasma after decanoate withdrawal.
    Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
    J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.
    Midha KK; Hubbard JW; Marder SR; Hawes EM; Van Putten T; McKay G; May PR
    Psychopharmacology (Berl); 1987; 93(3):369-73. PubMed ID: 3124166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The contribution of the in-vivo fate of an oil depot to drug absorption.
    Kalicharan RW; Oussoren C; Schot P; de Rijk E; Vromans H
    Int J Pharm; 2017 Aug; 528(1-2):595-601. PubMed ID: 28629984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.
    Chang SS; Javaid JI; Dysken MW; Casper RC; Janicak PG; Davis JM
    Psychopharmacology (Berl); 1985; 87(1):55-8. PubMed ID: 3933037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
    Turbott J; Villiger J; Hunter L
    Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Where does hydrolysis of nandrolone decanoate occur in the human body after release from an oil depot?
    Kalicharan RW; Bout MR; Oussoren C; Vromans H
    Int J Pharm; 2016 Dec; 515(1-2):721-728. PubMed ID: 27989828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
    Glazer WM; Friedhoff LT; Marder SR; Brown WA
    Schizophr Res; 1992 Dec; 8(2):111-7. PubMed ID: 1457388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitation of fluphenazine in equine serum following fluphenazine decanoate administration.
    Costello S; Heffron B; Taddei L; Benoit M; Hurt L; Simpson L; Bishop J; Folker-Calderon D; Negrusz A
    J Anal Toxicol; 2013 Oct; 37(8):594-9. PubMed ID: 23986099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late-Onset Rhabdomyolysis Associated With an Intramuscular Injection of Fluphenazine Decanoate.
    Umino M; Kobayashi R; Nisijima K; Suda S
    Prim Care Companion CNS Disord; 2017 Sep; 19(5):. PubMed ID: 28972705
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of bis(t-butyl-SATE)-AZTMP, a bispivaloylthioethyl prodrug for intracellular delivery of zidovudine monophosphate, in mice.
    Tan X; Boudinot FD; Chu CK; Egron D; Perigaud C; Gosselin G; Imbach JL
    Antivir Chem Chemother; 2000 May; 11(3):203-11. PubMed ID: 10901291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.